A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Jul 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
Indications Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer
Focus Therapeutic Use

06 Jun 2023 Results (n=22) assessing the efficacy and safety of durvalumab in combination with tremelimumab with and without radio frequency ablations in advanced biliary tract carcinoma, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
19 Apr 2023 Results (n=28) assessing Immune cell dynamics of patients with hepatocellular carcinoma treated with anti-PD-L1 plus anti-CTLA-4 combination therapy presented at the 114th Annual Meeting of the American Association for Cancer Research
06 Mar 2023 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com